ScoreWhy is Cyfuse Biomedical KK ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -371.81% of over the last 5 years
3
With a growth in Net Sales of 500.77%, the company declared Outstanding results in Dec 25
- RAW MATERIAL COST(Y) Fallen by -1,244.41% (YoY)
- INVENTORY TURNOVER RATIO(HY) Highest at 2.01 times
- DEBTORS TURNOVER RATIO(HY) Highest at 4.22 times
4
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -36.79%, its profits have fallen by -48%
5
Underperformed the market in the last 1 year
- Even though the market (Japan Nikkei 225) has generated returns of 41.20% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -36.79% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Cyfuse Biomedical KK should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Cyfuse Biomedical KK for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Cyfuse Biomedical KK
-36.79%
-0.36
47.53%
Japan Nikkei 225
41.2%
1.45
28.34%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
33.40%
EBIT Growth (5y)
-371.81%
EBIT to Interest (avg)
-84.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.23
EV to EBIT
-6.32
EV to EBITDA
-6.58
EV to Capital Employed
14.71
EV to Sales
84.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-232.72%
ROE (Latest)
-33.86%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -1,244.41% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 2.01 times
DEBTORS TURNOVER RATIO(HY)
Highest at 4.22 times
NET SALES(Q)
Highest at JPY 169.04 MM
OPERATING PROFIT(Q)
Highest at JPY -128.62 MM
OPERATING PROFIT MARGIN(Q)
Highest at -76.09 %
PRE-TAX PROFIT(Q)
Highest at JPY -126.03 MM
NET PROFIT(Q)
Highest at JPY -126.66 MM
EPS(Q)
Highest at JPY -12.09
-12What is not working for the Company
INTEREST(Q)
Highest at JPY 5.34 MM
Here's what is working for Cyfuse Biomedical KK
Net Sales
At JPY 169.04 MM has Grown at 500.77%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (JPY MM)
Net Sales
Highest at JPY 169.04 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY -128.62 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at -76.09 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY -126.03 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY -126.66 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY -12.09
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Inventory Turnover Ratio
Highest at 2.01 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 4.22 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -1,244.41% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at JPY 9.57 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Cyfuse Biomedical KK
Interest
At JPY 5.34 MM has Grown at 52.17%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Interest
Highest at JPY 5.34 MM
in the last five periods and Increased by 52.17% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
